Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- NCNO +12%, NOAH +9.6%, OUST +5.2%, KMB +2% (provides longer-term outlook in investor presentation; reaffirms FY24 guidance)
Other news:
- NVCR +30% (phase 3 METIS clinical trial met its primary endpoint)
- STKS +14.7% (to acquire Safflower Holdings, owner of Benihana, for $365 mln)
- MNOV +6.6% (Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan)
- ROIV +5.8% (to join S&P MidCap 400)
- MRK +4.5% (FDA approves Winrevair)
- SLND +4.5% (subsidiary Oscar Renda Contracting has been awarded a $56 million contract to construct a new wastewater treatment plant facility in the Southwest)
- MRNA +4.2% (advances multiple vaccine programs to late-stage clinical trials; Blackstone Life Sciences (BX) announces collaboration to support Moderna's influenza program)
- ATAI +3.5% (announces positive initial results from Beckley Psytech's phase 2a open label study of bpl-003 (intranasal 5-meo-dmt) in treatment resistant depression) LBPH +3.2% (entered into a Non-Voting Common Stock Purchase Agreement with an investment fund affiliated with Farallon Capital Management)
- RUN +3% (to move to S&P SmallCap 600 from S&P MidCap 400)
- GPRO +2.7% (to reduce global workforce by 4%)
- STOK +2% ($75 mln stock offering)
- BTBT +1.8% (customer proposes expansion by 2,048 GPUs)
- AZN +1.8% (Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer; AstraZeneca and Sanofi's (SNY) Beyfortus approved in Japan for the prevention of RSV disease in infants)
- MITT +1.5% (files $1 bln mixed shelf securities offering)
- NVAX +1.1% (co and Fujifilm settle disputes)
Analyst comments:
- OTLK +7.8% (upgraded to Buy from Neutral at BTIG Research)
- DB +3.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- THC +1.8% (upgraded to Outperform from Peer Perform at Wolfe Research)
- SLG +1.2% (upgraded to Equal Weight from Underweight at Barclays)